Compare Lennar Corporation (LEN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Lennar Corporation trades at $82.1 (market cap $19.92B), while State Street SPDR S&P Biotech ETF trades at $153.36. The key difference: Lennar Corporation pays a 2.41% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lennar Corporation nearer its low. Which is the better fit depends on your goals.
| LEN | XBI | |
|---|---|---|
Market Cap | $19.92B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $142.40 | $164.28 |
52-Week Low | $82.30 | $85.16 |
Enterprise Value | $23.80B | — |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $82.53, down 1.62% today, with a bearish technical signal and recent earnings misses. The stock shows attractive valuation metrics with a P/E of 13.15 and P/S of 0.64, but faces margin compression as net income fell to $2.08 billion in 2025. Recent news highlights housing affordability challenges and the company's strategy to prioritize volume over price, with average selling prices at 2017 levels (The Motley Fool, June 24, 2026).
The outlook is mixed: analyst consensus is a Buy with a $84.78 target, but technicals and earnings trends suggest near-term pressure. Key risks include rising mortgage rates and housing demand softness, while potential catalysts include margin recovery efforts and supportive housing legislation. Execution on cost discipline and market share gains will be critical for upside.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
